Labaran Waya

Sakamako Masu Alkawari a Sabon Nazarin Ciwon Kankara Na Kan Kan Kaya

Written by edita

SIWA Therapeutics, Inc., wani kamfani na biopharmaceutical na Chicago ya sanar a yau cewa SIWA's mallakin ɗan adam monoclonal antibody, SIWA318H, yana da inganci a cikin ingantaccen ƙirar ƙirar linzamin kwamfuta na xenograft don ciwon daji na pancreatic. Cibiyar bincike ta Translational Genomics ("TGEN") ce ta gudanar da binciken, bisa ga yarjejeniyar bincike da SIWA ta dauki nauyinta.

Sakamako na binciken ciwon daji na pancreatic a cikin berayen da aka yi amfani da su tare da SIWA318H sun haɗa da:

• Dukansu SIWA318H babban kashi da ƙananan ƙungiyoyin jiyya sun nuna gagarumin aikin anti-tumor a cikin samfurin ciwon daji na ciwon daji na PSN1 na ɗan adam na pancreatic linzamin kwamfuta na xenograft ta hanyar rage girman ƙwayar ƙwayar cuta (P-Value <0.0001);

• Akwai adadi mafi girma mafi girma na cikakkun shari'o'in gafara a cikin ƙungiyoyin da aka jiyya idan aka kwatanta da ƙungiyar kulawa ta isotype.

o 37.5% (6 daga cikin mice 16) da aka yi da SIWA318H babban kashi yana da cikakkiyar amsawa; (P-darajar = 0.0325)

o 43.8% (7 daga cikin mice 16) da aka yi da SIWA318H ƙananan kashi yana da cikakkiyar amsawa; (P-darajar = 0.0143)

• SIWA318H berayen da aka yi wa magani sun sami kyakkyawar rayuwa fiye da kwanaki 45 idan aka kwatanta da kwanaki 26 kacal na rayuwa ta tsakiya don sarrafa dabbobi, yana ba da shawarar yuwuwar fa'idar asibiti don maganin ciwon daji na pancreatic a cikin mutane.

• Babu wani bambance-bambance masu mahimmanci a cikin sauye-sauyen nauyin jiki tsakanin ƙungiyoyin kulawa da kulawa, yana nuna SIWA318H a cikin allurai da aka yi amfani da su da kyau.

"Mun gamsu da sakamakon SIWA318H a cikin wannan binciken da kuma abin da wannan ke nufi a yaki da ciwon daji," in ji Lewis Gruber, Shugaba da Babban Jami'in Kimiyya na SIWA. “SIWA ta ci gaba da kai hare-hare biyu kan cutar kansa ta hanyar amfani da SIWA318H don kawar da ƙwayoyin cutar kansa da kuma ƙwayoyin jijiya a cikin ƙananan ƙwayoyin tumor da ke tallafa musu. Mun yi imanin wannan ikon da za a iya kaiwa ga ƙwayoyin kansa guda biyu da ƙwayoyin ji na jiki yana sa SIWA318H ta zama cikakkiyar rigakafi don kusan dukkanin cututtukan daji da kuma dakatar da ci gaban cutar kansa, metastasis, da sake dawowa. ”

SIWA ya nuna cewa dangane da sakamakonsa tare da ciwon daji na pancreatic da metastasis, kuma bisa sakamakon da ke nuna raguwar ƙididdiga a cikin ƙwayar huhu a cikin samfurin linzamin kwamfuta na 4T1 na ciwon nono mara kyau sau uku ta amfani da homolog na SIWA318H (P-darajar ≤ 0.001), yana tsammanin. don shigar da IND ta farko tare da FDA a cikin 2023 don ciwon daji na pancreatic. Hakanan yana tsammanin buƙatar FDA ta ba da zaɓi na FastTrack.

Babu alamun wannan post.

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...